Cyclerion
BioTech/Drugs - Cambridge, Massachusetts, US
Cyclerion Employees
Christopher Winrow
Senior Director, Clinical Development - Neuroscience Program Lead
Cyclerion Details
Our current portfolio includes novel clinical-stage assets, namely praliciguat and olinciguat, as well as multiple research stage molecules. Praliciguat is a systemic sGC stimulator that is exclusively licensed to Akebia and is being advanced in rare kidney disease. Olinciguat is a vascular sGC stimulator that Cyclerion intends to develop itself or out-license for cardiovascular diseases. Concurrently, we are also evaluating other activities aimed at enhancing shareholder value, which potentially include collaborations, licenses, mergers, acquisitions and/or other targeted investments. In addition, Cyclerion holds 10 percent equity ownership in Tisento Therapeutics as part of an asset purchase agreement in which Tisento acquired the brain-penetrant sGC stimulators zagociguat and CY3018.
Cyclerion Technologies
Email Providers
Outlook
CMS
WordPress.org
Fonts
Google Font API
Search Marketing
Adobe Marketing Cloud
Recruitment
ADP
Hosting
Flywheel